Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Eng, Kevin H ^a   Tsuji, Takemasa ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTOME; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RELATED GENE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; REPRESSOR GENE; SIGNAL TRANSDUCTION; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TUMOR GENE; UPREGULATION; VERY ELDERLY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; SURVIVAL ANALYSIS; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84915815305     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111586     Document Type: Article

References (26)

1. Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, et al. (2012) High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clinical Cancer Research 18: 1374-1385.
2. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
3. Gnjatic S, Ritter E, Büchler MW, Giese NA, Brors B, et al. (2010) Seromic profiling of ovarian and pancreatic cancer. Proceedings of the National Academy of Sciences 107: 5088-5093.
4. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, et al. (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ t cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of Sciences 107: 7875-7880.
5. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 10: 942-949.
6. Qian F, Gnjatic S, Jager E, Santiago D, Jungbluth A, et al. (2004) Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1∗0401/0402 patients with epithelial ovarian cancer. Cancer Immunology 4: 12.
7. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine 348: 203-213.
8. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL (2011) Immunity and immune suppression in human ovarian cancer. Immunotherapy 3: 539-556.
9. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
10. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high cd8+/regulatory t cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences 102: 18538-18543.
11. Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, et al. (2008) Recognition of naturally processed and ovarian cancer reactive CD8+ t cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunology Immunotherapy 57: 1185-1195.
12. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer 11: 719-725.
13. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advancedstage ovarian cancer. Journal of Clinical Oncology 25: 517-525.
14. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research 14: 5198-5208.
15. Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, et al. (2008) Increased hla-dmb expression in the tumor epithelium is associated with increased ctl infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clinical Cancer Research 14: 7667-7673.
16. Leffers N, Fehrmann R, Gooden M, Schulze U, Ten Hoor K, et al. (2010) Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. British Journal of Cancer 103: 685-692.
17. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, et al. (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nature communications 4.
18. Baggerly KA, Coombes KR, Neeley ES (2008) Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. Journal of Clinical Oncology 26: 1186-1187.
19. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, et al. (2007) A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proceedings of the National Academy of Sciences 104: 13086-13091.
20. Almeida LG, Sakabe NJ, Silva MCC, Mundstein AS, Cohen T, et al. (2009) CTdatabase: a knowledge-base of high-throughput and curated data on cancertestis antigens. Nucleic Acids Research 37: D816-D819.
21. Carlson M (2014) hthgu133a.db: Affymetrix HT Human Genome U133 Array Plate Set annotation data (chip hthgu133a). R package version 2.8.0.
22. Schaefer J, Opgen-Rhein R, Strimmer K (2013) GeneNet: Modeling and Inferring Gene Networks. URL http://CRAN.R-project.org/package=GeneNet. R package version 1.2.8.
23. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, et al. (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proceedings of the National Academy of Sciences 101: 6062-6067.
24. Emery P, Durand B, Mach B, Reith W (1996) RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom. Nucleic Acids Research 24: 803-807.
25. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nature Reviews Cancer 5: 615-625.
26. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, et al. (2013) Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. The Journal of clinical investigation 123: 517-525.